82 completed, 13 recruiting, 13 terminated, 6 withdrawn. 57 Phase 1, 28 Phase 2, 20 Phase 4, 15 Phase 3, 10 Not applicable.
Follow Famotidine: new trials by email Literature Review of Famotidine trials Research Report on Famotidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults Osivelotor, Famotidine - Healthy | Phase 1 | Recruiting | Pfizer | 52 | 2026-09-18 | 2026-10-21 |
| Paracetamol and Ibuprofen With or Without Famotidine for Calcific Tendinitis of the Shoulder Paracetamol + Ibuprofen + Famotidine, Paracetamol + Ibuprofen - Calcific Tendinitis | Not applicable | Not yet recruiting | University Hospital Dubrava | 200 | 2026-09-01 | 2026-04-20 |
| Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib Taletrectinib, Taletrectinib, Famotidine, Taletrectinib,Famotidine - Healthy Adult Participants | Phase 1 | Not yet recruiting | Nuvation Bio Inc. | 56 | 2026-08-01 | 2026-08-03 |
| Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants BMS-986533, Famotidine, Placebo - Healthy Volunteers | Phase 1 | Recruiting | Bristol-Myers Squibb | 136 | 2026-07-13 | 2026-07-24 |
| Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial Acetaminophen, Biospecimen Collection, Dexamethasone - Multiple Myeloma | Phase 4 | Recruiting | Emory University | 94 | 2025-09-24 | 2026-07-23 |
| Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole - Healthy | Phase 1 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 24 | 2025-08-21 | 2026-05-08 |
| Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia Tegoprazan, Famotidine, Placebo - General Anesthesia | Phase 4 | Enrolling by invitation | Seok Kyeong Oh | 174 | 2025-07-23 | 2025-09-05 |
| A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants INCB161734, Itraconazole, Rifampin - Healthy Participants | Phase 1 | Completed | Incyte Corporation | 63 | 2025-07-16 | 2025-11-26 |
| A Study to Prevent Infantile Spasms Relapse Prednisolone, Famotidine, Placebo - Infantile Spasms, Infantile Epileptic Spasms Syndrome | Phase 2 | Recruiting | University of California, Los Angeles | 40 | 2025-05-05 | 2025-05-08 |
| Novel Strategies for Reducing Burn Scar Itch Famotidine and 4% topical cromolyn sodium, Placebo - Burn Scar, Itch Scarring | Phase 3 | Recruiting | The University of Texas Medical Branch, Galveston | 44 | 2025-03-01 | 2026-10-05 |
| Gastrointestinal Dysmotility on Aspiration Risk Prucalopride, Famotidine - Esophageal Motility Disorders, Gastric Motor Dysfunction | Phase 4 | Recruiting | Boston Children's Hospital | 120 | 2025-02-13 | 2026-08-03 |
| Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) Protonix (Pantoprazole) 40 mg q 12 hrs for 3 days, Pepcid (Famotidine) 20 mg q 12 hrs for 3 days - Acute Kidney Injury | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | 400 | 2025-01-24 | 2025-05-14 |
| A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults Deucravacitinib, Famotidine - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 26 | 2025-01-23 | 2025-04-29 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| Exploring Novel Therapeutic Approaches for Disorders of Gut-Liver-Brain Interaction-H1/H2 Famotidine, Levocetirizine, Fuyuan Gasmin - Functional Gastrointestinal Disorders | Phase 2 | Recruiting | Buddhist Tzu Chi General Hospital | 45 | 2025-01-01 | 2026-10-05 |
| A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers NX-5948, Esomeprazole, Placebo - Healthy Volunteer | Phase 1 | Completed | Nurix Therapeutics, Inc. | 223 | 2024-11-30 | 2026-07-28 |
| A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease BMS-986470, Placebo, Famotidine - Anemia, Sickle Cell, Healthy Volunteers | Phase 1 / Phase 2 | Recruiting | Bristol-Myers Squibb | 224 | 2024-07-17 | 2026-08-18 |
| Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery Acetaminophen, Celebrex, Gabapentin - Spinal Disorder | Phase 3 | Withdrawn | University of Miami | 2024-06-01 | 2025-06-03 | |
| Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors H1 receptor blockade: 540 mg (Allegra), H2 receptor blockade: 40 mg (Pepcid AC) - Prehypertension (elevated Blood Pressure) or Hypertension | Not applicable | Completed | California Baptist University | 10 | 2024-04-01 | 2024-10-08 |
| PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects Tegoprazan 12.5mg, Tegoprazan 25mg, Famotidine 20mg - Healthy | Phase 1 | Unknown | HK inno.N Corporation | 36 | 2024-03-19 | 2024-03-27 |
Showing 20 of 123. Sign in to see all of them.
COVID-19 (14) · Gastroesophageal Reflux (6) · Peptic Ulcer (5) · Gastrointestinal Hemorrhage (4) · Breast Neoplasms (3) · Dyspepsia (3) · Heartburn (3) · Stomach Neoplasms (3) · Acute Coronary Syndrome (2) · Acute Kidney Injury (2) · Anemia, Sickle Cell (2) · Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Gastrointestinal Diseases (2)
Bristol-Myers Squibb (18) · Emory University (4) · M.D. Anderson Cancer Center (4) · Ruttonjee Hospital (4) · Leidos Life Sciences (3) · National Cancer Institute (NCI) (3) · Pfizer (3) · Amgen (2) · Boston Children's Hospital (2) · Chinese University of Hong Kong (2) · Far Eastern Memorial Hospital (2) · Incyte Corporation (2) · Jesper Ekelund (2) · Kaohsiung Veterans General Hospital. (2) · Merck Sharp & Dohme LLC (2)
United States (68) · United Kingdom (7) · Australia (5) · China (5) · Taiwan (5) · Canada (4) · Egypt (3) · Germany (3) · Japan (3) · Belgium (2) · Finland (2) · France (2) · India (2) · Italy (2) · Netherlands (2)
Brian A Roberts, MS, PMP (2) · Fook Hong Ng, MBBS (2) · Yafen Liang, MD (2) · Alicia M. Kowalski, MD (1) · Ben D Albert, MD (1) · Beth Helmink, MD (1) · Brian Badgwell, MD (1)
PMID 34473343, PMID 20379093, PMID 22093203, PMID 22108447, PMID 23630016, PMID 23764683, PMID 23856153, PMID 25906190, PMID 26165391, PMID 27641510, PMID 31229990, PMID 32600393, PMID 33394214, PMID 36325947, PMID 36883141, PMID 37722599, PMID 38240536, PMID 38842838, PMID 39592213, PMID 39604046, PMID 39761829, PMID 40462830, PMID 40762274, PMID 41425223, PMID 42799508
2009 (1), 2019 (1), 2023 (1), P30CA138292 (1), R61HL142539 (1), UM1AI144298 (1)